Clinical, phenotypic and oncologic background differences in patients with sporadic, familial and multiple primary melanoma
Anais Brasileiros de Dermatologia · 2026-11 · 101 (6) · 501472
DOI: 10.1016/j.abd.2026.501472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2026-11. Verfasst von Irene López-Riquelme und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain; Instituto de Investigación Biomédica de Málaga-Plataforma BioNAN…. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Sporadic Melanoma (SM) refers to patients with a single melanoma and no family history. Multiple Primary Melanoma (MPM) includes individuals with two or more primary melanomas. Familial Melanoma (FM) is defined as melanoma occurring in two first-degree relatives, or in three or more affected family members of any degree. Previous studies describe distinct phenotypic and clinical profiles in each subgroup, and a high proportion of personal and familial cancer history in patients with melanoma. OBJECTIVE: To compare phenotype, clinicopathological features, and oncological history in the three groups. METHODS: Data from 442 patients were collected and divided into three groups: FM, MPM, and SM. RESULTS: The MPM group showed light eye color (p = 0.01), more tan 50 nevi (p = 0.00014), actinic keratoses (p = 0.0025), and melanomas arising from pre-existing nevi (p = 0.0031). FM patients were younger (p = 0.01) and had a higher burden of personal and family cancer history, particularly breast neoplasms (p = 0.01). SM presented ≥ 2 mitoses (p ≤ 0.0001). Multivariate analysis confirmed independent associations specific to each group. STUDY LIMITATIONS: Long term-follow-up for secondary melanoma is needed for validation. Also, some participants may not recall certain family history. CONCLUSION: Patients with MPM display fair phototypes, numerous nevi, and markers of chronic sun damage, suggesting a central role of phenotype and cumulative UV exposure. In FM, younger age and a higher burden of oncologic history point toward an underlying genetic predisposition. SM is characterized by fewer nevi and aggressive melanomas, reflecting a distinct biological entity. These findings highlight the complex interplay between genetic and environmental factors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain; Instituto de Investigación Biomédica de Málaga-Plataforma BioNAND, Málaga, Spain; Department of Medicine, Universidad de Málaga, Málag…
- Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain.
- Department of Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain; Instituto de Investigación Biomédica de Málaga-Plataforma BioNAND, Málaga, Spain; Department of Medicine, Universidad de Málaga, Málaga,…
Zitieren
APA
López-Riquelme, I., Martínez-García, S., Romero-Bravo, M., & Berciano-Guerrero, M. Á. (2026). Clinical, phenotypic and oncologic background differences in patients with sporadic, familial and multiple primary melanoma. Anais Brasileiros de Dermatologia, 101(6), 501472. https://doi.org/10.1016/j.abd.2026.501472
Vancouver
López-Riquelme I, Martínez-García S, Romero-Bravo M, Berciano-Guerrero MÁ. Clinical, phenotypic and oncologic background differences in patients with sporadic, familial and multiple primary melanoma. Anais Brasileiros de Dermatologia. 2026;101(6):501472. doi:10.1016/j.abd.2026.501472
BibTeX
@article{LpezRiquelme2026,
author = {López-Riquelme, Irene and Martínez-García, Silvestre and Romero-Bravo, Marina and Berciano-Guerrero, Miguel-Ángel},
title = {Clinical, phenotypic and oncologic background differences in patients with sporadic, familial and multiple primary melanoma},
journal = {Anais Brasileiros de Dermatologia},
year = {2026},
volume = {101},
number = {6},
pages = {501472},
doi = {10.1016/j.abd.2026.501472}
}
EUVIMED